HK1079811A1 - Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter - Google Patents

Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Info

Publication number
HK1079811A1
HK1079811A1 HK05111950.0A HK05111950A HK1079811A1 HK 1079811 A1 HK1079811 A1 HK 1079811A1 HK 05111950 A HK05111950 A HK 05111950A HK 1079811 A1 HK1079811 A1 HK 1079811A1
Authority
HK
Hong Kong
Prior art keywords
helicobacter
selection
lactic acid
acid bacteria
reducing inflammation
Prior art date
Application number
HK05111950.0A
Other languages
English (en)
Inventor
Bo Moellstam
Eamonn Connolly
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of HK1079811A1 publication Critical patent/HK1079811A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK05111950.0A 2002-10-07 2005-12-23 Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter HK1079811A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/265,859 US7105336B2 (en) 2002-10-07 2002-10-07 Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
PCT/SE2003/001552 WO2004031368A1 (en) 2002-10-07 2003-10-06 Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Publications (1)

Publication Number Publication Date
HK1079811A1 true HK1079811A1 (en) 2006-04-13

Family

ID=32042542

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111950.0A HK1079811A1 (en) 2002-10-07 2005-12-23 Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Country Status (15)

Country Link
US (4) US7105336B2 (es)
EP (1) EP1551952B1 (es)
JP (2) JP4804755B2 (es)
KR (2) KR101064058B1 (es)
CN (1) CN1694954B (es)
AU (1) AU2003269756B2 (es)
BR (1) BR0314511A (es)
DK (1) DK1551952T3 (es)
ES (1) ES2602679T3 (es)
HK (1) HK1079811A1 (es)
HU (1) HUE031627T2 (es)
MX (1) MXPA05003731A (es)
PT (1) PT1551952T (es)
WO (1) WO2004031368A1 (es)
ZA (1) ZA200502602B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
DK1567018T3 (da) * 2002-10-18 2009-09-14 Biogaia Ab Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer
US20050281756A1 (en) 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
WO2005079210A2 (en) * 2003-12-04 2005-09-01 Biofilms Strategies, Inc. Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria
CA2557834C (en) * 2004-03-04 2012-05-22 E-L Management Corporation Skin treatment method with lactobacillus extract
US7955834B2 (en) * 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
EP1703281A1 (fr) * 2005-03-16 2006-09-20 Compagnie Gervais Danone Souches bactériennes induisant une diminution de l'expression de Rbx1
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
DE102005062731A1 (de) 2005-12-22 2007-06-28 Organobalance Gmbh Neue Lactobacillus Stämme und deren Verwendung
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
KR20100014523A (ko) * 2007-02-22 2010-02-10 위르겐 슈레첸메이르 인간의 알레르기 반응을 예방, 억제 또는 제거하는 프로바이오틱 그램-양성 박테리아
CN101273736B (zh) * 2007-03-28 2012-08-08 北京弗蒙特生物技术有限公司 一种在常温下保持高活菌数的发酵乳的制备方法
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100886793B1 (ko) * 2007-06-26 2009-03-04 한경대학교 산학협력단 항균과 생균 활성을 가지는 신규한락토바실러스　코르니포미스 ｈｄ-０２ 균주 및 이의 용도
CN102115721B (zh) * 2008-05-08 2012-09-26 景岳生物科技股份有限公司 具有抗炎活性的乳杆菌分离株及其用途
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
US20110293710A1 (en) 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
WO2013027087A1 (en) 2011-08-23 2013-02-28 Compagnie Gervais Danone A non-reuterin-producing lactobacillus reuteri strain for treating helicobacter pylori infection
PL2785878T3 (pl) * 2011-11-30 2017-04-28 Compagnie Gervais Danone Lactobacillus brevis wytwarzający reuterynę
CN104684565A (zh) * 2012-05-29 2015-06-03 达努塔·克鲁谢夫斯卡 在人类和兽医的预防和医疗中有用的、包含罗伊氏乳杆菌dan080的纳米产品及其医疗用途
EP2912163A1 (en) 2012-10-25 2015-09-02 Compagnie Gervais Danone Streptococcus thermophilus strains for treating helicobacter pylori infection
EP3040412A4 (en) * 2013-08-23 2017-04-05 Consejo Superior De Investigaciones Científicas (CSIC) Probiotic strain of lactobacillus reuteri exhibiting anti-helicobacter activity, a probiotic or biotherapeutic product comprising said strain, and the use thereof
SG11201610250WA (en) 2014-07-01 2017-01-27 Probi Usa Inc Bi-layer dual release probiotic tablets

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
DE69223615T2 (de) * 1992-07-06 1998-04-09 Nestle Sa Lactobacillus Acidophilus enthaltende Antigastritis-Mittel
ATE474597T1 (de) * 1993-05-17 2010-08-15 Cytokine Pharmasciences Inc Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5534253A (en) 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
JP2001514873A (ja) * 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド 結合特性が改善されたアンチセンスおよびアンチジーン治療薬並びにそれらの使用方法
GB9719238D0 (en) * 1997-09-11 1997-11-12 Mathilda & Terence Kennedy Ins Viral infection of cells
MXPA00007815A (es) * 1998-02-11 2002-04-24 Neurochem Inc Metodo para modular la activacion de macrofagos.
CA2329160A1 (en) * 1998-06-11 1999-12-16 University Of Medicine & Dentistry Of New Jersey Wound treatment through inhibition of adenosine diphosphate ribosyl transferase
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP4509250B2 (ja) * 1999-06-24 2010-07-21 明治乳業株式会社 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品
JP3046303B1 (ja) * 1999-06-24 2000-05-29 明治乳業株式会社 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性飲食品
KR100357668B1 (ko) 2000-02-19 2002-10-18 주식회사 한국야쿠르트 헬리코박터 필로리에 대해 항균활성을 갖는 락토바실러스애시도필러스 에이치 와이 2177, 락토바실러스 카제이에이치 와이2743 및 그를 이용한 유산균 제제, 발효유
IL151345A0 (en) * 2000-02-23 2003-04-10 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001097821A1 (en) * 2000-06-19 2001-12-27 Mucoprotec Pty Ltd Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1432426A2 (en) * 2001-09-05 2004-06-30 ACTIAL Farmaceutica Lda. USE OF UNMETHYLATED CpG
US7105336B2 (en) * 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof

Also Published As

Publication number Publication date
JP5439315B2 (ja) 2014-03-12
CN1694954B (zh) 2010-05-12
US20060251636A1 (en) 2006-11-09
US20090110670A1 (en) 2009-04-30
US7960137B2 (en) 2011-06-14
KR20110033943A (ko) 2011-04-01
US20040067573A1 (en) 2004-04-08
JP4804755B2 (ja) 2011-11-02
CN1694954A (zh) 2005-11-09
ZA200502602B (en) 2006-06-28
PT1551952T (pt) 2016-11-23
KR101064058B1 (ko) 2011-09-08
US7105336B2 (en) 2006-09-12
EP1551952B1 (en) 2016-08-17
ES2602679T3 (es) 2017-02-22
US7678553B2 (en) 2010-03-16
EP1551952A1 (en) 2005-07-13
WO2004031368A1 (en) 2004-04-15
AU2003269756B2 (en) 2007-08-09
KR101107453B1 (ko) 2012-01-19
US20100129337A1 (en) 2010-05-27
AU2003269756A1 (en) 2004-04-23
JP2006501823A (ja) 2006-01-19
MXPA05003731A (es) 2005-06-17
DK1551952T3 (en) 2016-12-12
JP2011021015A (ja) 2011-02-03
HUE031627T2 (en) 2017-09-28
BR0314511A (pt) 2005-08-09
KR20050047107A (ko) 2005-05-19

Similar Documents

Publication Publication Date Title
HK1079811A1 (en) Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter
IN2006DE07653A (en) Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
EP1608308A4 (en) ANTI-INFLAMMATORY ACTIVITY OF LACTIC ACID BACTERIA
SI2548455T1 (sl) Sestavek, ki vsebuje mlečno kislinsko bakterijo, ki proizvaja ekvol
AU2003284115A8 (en) Method of delivering local anesthesia
HK1157760A1 (en) Benzimidazol-carbonyl-pyridinyl-amino-propionic acid ethyl ester hemihydrate and use thereof
EP1572262A3 (en) Method of delivering local anesthesia
EP1472021A4 (en) AMMONIAX OXIDIZING BACTERIA CONTAINING COMPOSITIONS AND USER METHOD THEREFOR
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
EP1868622A4 (en) SELECTION AND USE OF LACTIC ACID BACTERIA TO REDUCE INFLAMMATION IN MAMMALS
EP1511488A4 (en) HUMAN INHIBITORS OF ADAM 10
AU2003291700A8 (en) Oral hygiene system and method of treatment
ZA200701233B (en) Compositions and methods for dermatological wound healing
ZA200505679B (en) Nutritional formula comprising L(+)-lactic acid
AU2003287443A8 (en) Compositions and methods for pain reduction
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
EP1487776A4 (en) ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
AU2003232044A8 (en) Composition and method for dermatological treatment
HK1080453A1 (en) Intermediates in producing phenoxyacetic acid derivatives and method of using the same
EP1648399A4 (en) METHOD AND TOPIC COMPOSITION FOR TREATING SKIN HYPERPIGMENTATION
IL164267A0 (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AU2003291456A8 (en) Methods for promoting wound healing and uses thereof
PL376442A1 (en) Milk improved by treatment with proteases and methods for its preparation
EP1545287A4 (en) VASOREGULATORY COMPOUNDS AND METHODS RELATING TO THEIR USE
AU2003294684A8 (en) Ketoprofen compositions and methods of making them

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20231005